

Whole Body Scintigraphy Using ^{67}Ga
—Clinical analysis of 1000 Cases—

N. YUI, F. KINOSHITA and M. KOAKUTSU

Division of Nuclear Medicine, Chiba Cancer Center Hospital

In past four years we have experienced 1457 times of whole body scintigraphy using ^{67}Ga with 1051 patients. Evaluating those experiences 315 out of 426 patients of malignant tumors, 74 per cent, without any treatment showed abnormal deposit on primary lesion. Cases of carcinoma of head and neck region, lung and esophagus and sarcoma of soft part showed relatively high positive ratio, and that of abdominal and pelvic region showed low ratio. Including recurrent cases, whole body scintigraphy was performed 1120 times concerning patients of

malignant tumors and ratio that showed abnormal deposits on both primary and metastatic lesion was 61 per cent and that on either primary or metastatic was 88 per cent. We performed this examination for the purpose of detecting primary region about 57 patients who had been diagnosed only metastatic lesions and found out of 17 primary lesions, that was 30 per cent. We conclude that whole body scintigraphy using ^{67}Ga is useful for detecting some malignant focuses in either primary or secondary case.

^{201}Tl -Bleomycin, A Tumor-Localizing Agent

Masanao KAWANA, Noboru ARIMIZU, Hiromichi AKIBA and Keiko IMAZEKI

Dept. of Radiology, Chiba University Hospital

The purpose of this study is to test ^{201}Tl -Bleomycin for use as a tumor localizing agent.

The anti-neoplastic, Bleomycin, has been labeled with several radionuclides. Mice with transplanted tumor were examined the sensitivity and specificity of ^{201}Tl -Bleomycin. We have studied the images in 14 patients with known tumor. The tumor visualized immediately after venous injection, but better scintigrams were obtained at 5–15 minutes. ^{67}Ga citrate uptakes were superior to those of ^{201}Tl -Bleomycin. All 14 patients showed increased Bleomycin uptakes in tumor, but increased uptakes were also demonstrated in kidney and heart. It is concluded that ^{201}Tl -Bleomycin appears to be a useful tumor localizing agent.

Clinical Results of ^{201}Tl -Bleomycin
Scintiscannings

| | | | |
|------|-----|------------------------|-----|
| K.T. | 68y | Lung Ca. | (+) |
| M.T. | 45y | Esophag. Ca. meta | (+) |
| K.S. | 69y | Neck Tumor | (+) |
| K.M. | 54y | Malignant Lymphoma | (+) |
| M.H. | 28y | Mediastinal Tumor | (+) |
| I.T. | 68y | Struma Malignum meta | (+) |
| H.T. | 49y | Lung Ca. | (+) |
| R.K. | 76y | Mandibular Ca. | (+) |
| Y.A. | 72y | Struma malignum | (+) |
| Y.T. | 86y | Skin Ca. meta | (+) |
| M.T. | 39y | Breast Ca. meta | (+) |
| H.S. | 61y | Pharyngeal Ca. | (+) |
| T.H. | 33y | Glioblastoma | (+) |
| T.Y. | 38y | Eosinophilic granuloma | (+) |